Johnson & Johnson (JNJ) said Monday it will present the latest data from the TAR-200 study to treat patients with Bacillus Calmette-Guerin-unresponsive, high-risk non-muscle-invasive bladder cancer with carcinoma in situ with or without papillary disease at the American Urological Association on April 26.
The 12-month duration of response findings from cohort 2 of the phase 2b trial evaluating the TAR-200 monotherapy revealed a positive complete response rate, according to a statement.
The company said it will also present the first results from cohort 4 of the phase 2b trial for patients with papillary-only, high-risk non-muscle invasive bladder cancer.
Price: 157.83, Change: +0.35, Percent Change: +0.23
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.